Hives remedy developer Third Harmonic Bio (THRD) has priced its upsized $185M preliminary public providing.
The biotech firm mentioned it now plans to supply 10.9M shares at $17 per share. Underwriters will probably be granted a 30-day possibility to purchase as much as 1.64M further shares.
Morgan Stanley, Jefferies and Cowen are serving as joint bookrunners, with LifeSci Capital appearing as co-manager.
Primarily based in Cambridge, Mass., Third Harmonic’s lead product, THB001, is a KIT inhibitor being developed as a attainable remedy for power uticaria, often known as hives.
The deal was upsized from an earlier proposal this month that had the corporate providing 9M shares priced between $16 and $18, which might have raised roughly $153M if priced on the midpoint.